NANJING, China , June 6, 2024 /PRNewswire/ -- Tuniu Corporation (Nasdaq: TOUR) ("Tuniu" or the "Company"), a leading online leisure travel company in China, today announced that it has received a not...
NANJING, China , June 5, 2024 /PRNewswire/ -- Tuniu Corporation (Nasdaq: TOUR) ("Tuniu" or the "Company"), a leading online leisure travel company in China, today announced that it has received a noti...
NANJING, China , June 4, 2024 /PRNewswire/ -- Tuniu Corporation (NASDAQ: TOUR) ("Tuniu" or the "Company"), a leading online leisure travel company in China, today announced its unaudited financial res...
Schauffele earns his first major victory and sets the lowest winning score in major championship history with a Callaway Paradym Ai Smoke Driver, Chrome Tour Golf Ball, and an Odyssey Putter CARLSBAD,...
MIAMI--(BUSINESS WIRE)--Perry Ellis International, marca internacional de moda, expondrá en la 2024 Licensing Expo de Las Vegas su impresionante gama de marcas de moda y estilo de vida: Perry Ellis®...
MIAMI--(BUSINESS WIRE)--Das globale Modehaus Perry Ellis International wird auf der 2024 Licensing Expo in Las Vegas ausstellen und sein beeindruckendes Portfolio an Mode- und Lifestyle-Marken präsen...
MIAMI--(BUSINESS WIRE)--La maison de couture mondiale Perry Ellis International participera au salon Licensing Expo 2024 de Las Vegas. Elle y présentera son impressionnant portefeuille de marques de ...
MIAMI--(BUSINESS WIRE)--Het wereldwijde modehuis Perry Ellis International zal aanwezig zijn op de 2024 Licensing Expo in Las Vegas waar het zijn indrukwekkende portfolio van mode- en lifestylemerken ...
MIAMI--(BUSINESS WIRE)--Global fashion house, Perry Ellis International, will be exhibiting at the 2024 Licensing Expo in Las Vegas featuring its impressive portfolio of fashion and lifestyle brands s...
NANJING, China , May 20, 2024 /PRNewswire/ -- Tuniu Corporation (NASDAQ:TOUR) ("Tuniu" or the "Company"), a leading online leisure travel company in China, today announced that it plans to release its...
– First patient dosed in trial to evaluate the safety, pharmacokinetics and pharmacodynamics of TOUR006 in patients with inflammatory risk and chronic kidney disease – – Topline data anticipated...